These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28215291)

  • 1. Crystal Structures of Neurotrophin Receptors Kinase Domain.
    Bertrand T
    Vitam Horm; 2017; 104():1-18. PubMed ID: 28215291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
    Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
    J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
    Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The crystal structures of TrkA and TrkB suggest key regions for achieving selective inhibition.
    Bertrand T; Kothe M; Liu J; Dupuy A; Rak A; Berne PF; Davis S; Gladysheva T; Valtre C; Crenne JY; Mathieu M
    J Mol Biol; 2012 Oct; 423(3):439-53. PubMed ID: 22902478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains.
    Zaccaro MC; Ivanisevic L; Perez P; Meakin SO; Saragovi HU
    J Biol Chem; 2001 Aug; 276(33):31023-9. PubMed ID: 11425862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimerization of the Trk receptors in the plasma membrane: effects of their cognate ligands.
    Ahmed F; Hristova K
    Biochem J; 2018 Nov; 475(22):3669-3685. PubMed ID: 30366959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trk kinase inhibitors as new treatments for cancer and pain.
    Wang T; Yu D; Lamb ML
    Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity in Trk receptor:neurotrophin interactions: the crystal structure of TrkB-d5 in complex with neurotrophin-4/5.
    Banfield MJ; Naylor RL; Robertson AG; Allen SJ; Dawbarn D; Brady RL
    Structure; 2001 Dec; 9(12):1191-9. PubMed ID: 11738045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tyrosine kinase domain properties for the neurotrophin receptors TrkA and TrkB.
    Artim SC; Kiyatkin A; Lemmon MA
    Biochem J; 2020 Oct; 477(20):4053-4070. PubMed ID: 33043964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 bind to a single leucine-rich motif of TrkB.
    Windisch JM; Marksteiner R; Lang ME; Auer B; Schneider R
    Biochemistry; 1995 Sep; 34(35):11256-63. PubMed ID: 7669784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of neurotrophin expression and activity in the retina.
    Hackam AS
    Adv Exp Med Biol; 2008; 613():343-9. PubMed ID: 18188963
    [No Abstract]   [Full Text] [Related]  

  • 16. Intracellular LINGO-1 negatively regulates Trk neurotrophin receptor signaling.
    Meabon JS; de Laat R; Ieguchi K; Serbzhinsky D; Hudson MP; Huber BR; Wiley JC; Bothwell M
    Mol Cell Neurosci; 2016 Jan; 70():1-10. PubMed ID: 26546150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational basis for Trk inhibition therapy for prostate cancer.
    Weeraratna AT; Arnold JT; George DJ; DeMarzo A; Isaacs JT
    Prostate; 2000 Oct; 45(2):140-8. PubMed ID: 11027413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular interactions between neurotrophin receptors.
    Dechant G
    Cell Tissue Res; 2001 Aug; 305(2):229-38. PubMed ID: 11545260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrazolo[1,5-
    Mahajan AT; Shivani ; Datusalia AK; Coluccini C; Coghi P; Chaudhary S
    Molecules; 2024 Jul; 29(15):. PubMed ID: 39124968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
    Chen L; Chen Y; Zhang C; Jiao B; Liang S; Tan Q; Chai H; Yu W; Qian Y; Yang H; Yao W; Yu J; Luo Y; Plewe M; Wang J; Han XR; Liu J
    J Med Chem; 2020 Dec; 63(23):14562-14575. PubMed ID: 33058680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.